Resources for schools and students We are passionate about inspiring the cancer researchers of the future. We engage with local secondary schools in Sutton, Kensington and Chelsea and the surrounding ...

Our leadership teamProfessor Kristian Helin Chief Executive and President The Chief Executive is responsible to the Board of Trustees for the overall direction of the ICR’s management, research and ...

The Division of Breast Cancer Research, which incorporates the Breast Cancer Now Research Centre, contains over 100 scientists and clinicians working in 19 groups.

The Adult Drug Development Unit (DDU) and The Royal Marsden NHS Foundation Trust, is a group focused on early anti-cancer drug development.

The London Cancer Hub is a collaboration between The Institute of Cancer Research, London, and the London Borough of Sutton, with the support of The Royal Marsden NHS Foundation Trust and the Greater ...

Give a monthly donation to help us stay one step ahead of cancer with new smarter and targeted treatments – so that more people will survive blood cancer. Cecelia Brunott (pictured above) was ...

Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy.

We have made huge strides in research and treatment for children with cancer, improving their chances of survival. With your support today, we can discover kinder treatments and offer more children ...

From supermarket collections to cake sales, bike rides or fun runs, there are so many ways you can fundraise for The Institute of Cancer Research. Our scientists and clinicians are working in our labs ...

Corporate governance The overall governing body of The Institute of Cancer Research is its Board of Trustees. The Board is supported by a number of sub-committees: Executive Board Audit & Risk ...

This course is organised by the Joint Department of Physics of The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London.

Twenty years ago, a detailed draft and analysis of the human genome was completed. In this feature, Diana Cano Bordajandi looks at the lasting legacy of the Human Genome Project.